![]() |
市場調查報告書
商品編碼
1792369
神經血管內線圈市場報告(按產品類型(Guglielmi 可分離線圈、矩陣線圈)、適應症、應用、最終用戶(醫院、門診手術中心、中風中心等)和地區)2025 年至 2033 年Neuroendovascular Coil Market Report by Product Type (Guglielmi Detachable Coils, Matrix Coils), Indication, Application, End User (Hospitals, Ambulatory Surgical Centers, Stroke Centers, and Others), and Region 2025-2033 |
2024 年全球神經血管內線圈市場規模達 10.252 億美元。展望未來, IMARC Group預計到 2033 年市場規模將達到 12.839 億美元,2025-2033 年期間的成長率 (CAGR) 為 2.66%。
神經血管內栓塞術是一種微創血管內治療,用於阻斷腦血管血流。動脈瘤是由血管壁薄弱引起的膨脹,可能因壓力升高而破裂並導致出血進入腦部。動脈瘤破裂的症狀通常包括突發性劇烈頭痛、噁心、嘔吐、視力模糊或複視、癲癇發作。在神經血管內栓塞術中,外科醫生使用可拆卸的鉑金彈簧圈緊緊地塞住動脈瘤,以促進血液凝固並降低外壁壓力。神經血管內栓塞術因其成本低廉且患者風險低而在全球範圍內越來越受歡迎。
神經血管內彈簧圈技術在形狀、長度和生物活性方面取得了多項進展。此外,顱內支架在部署和傳輸方面也取得了顯著進展。外科醫生已開始將顱內支架與彈簧圈技術結合,以治療動脈瘤並減少復發相關問題。此外,就術後併發症、良好療效和復健而言,血管內彈簧圈被認為是一種比夾閉術更好的手術技術。除此之外,各種市場參與者都在投資引進技術先進的產品。例如,2018 年,強生醫療器材公司的子公司 Cerenovus 推出了 Galaxy G3 Mini 栓塞彈簧圈,該彈簧圈採用不規則形狀設計,使其能夠填充腦動脈瘤中的開放空間。
IMARC 集團的最新報告深入洞察了全球神經血管內線圈市場,涵蓋了其所有重要方面。報告涵蓋了從市場宏觀概覽到產業表現的微觀細節、近期趨勢、關鍵市場促進因素和挑戰、SWOT 分析、波特五力模型分析、價值鏈分析等。對於企業家、投資者、研究人員、顧問、商業策略家以及所有持有或計劃以任何方式進入神經血管內線圈市場的人士而言,本報告都是必讀之作。
The global neuroendovascular coil market size reached USD 1,025.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,283.9 Million by 2033, exhibiting a growth rate (CAGR) of 2.66% during 2025-2033.
Neuroendovascular coiling is a minimally invasive endovascular treatment which is performed to block the blood flow in a blood vessel in the brain. It is essential to treat an aneurysm, a bulge caused by weakness in the wall of a blood vessel, which can rupture due to rising pressure and bleed into the brain. The symptoms of a ruptured aneurysm generally include sudden onset of a severe headache, nausea, vomiting, blurred or double vision, and seizure. In neuroendovascular coiling, a surgeon tightly packs the aneurysm with detachable platinum coils that promote blood clotting and reduce pressure on the outer wall. Neuroendovascular coiling is becoming popular across the globe as it incurs less cost and lowers the risk for the patients.
Several advances have been made in the neuroendovascular coil technology in terms of shape, length and bioactivity. Besides this, significant progress has been made in intracranial stents to improve their deployment and delivery. Surgeons have started integrating intracranial stents with the coil technology to treat aneurysms and reduce issues related to recurrence. Moreover, endovascular coiling is being considered a better surgical technique than clipping regarding postoperative complications, favorable outcomes and rehabilitation. Other than this, various market players are investing in the introduction of technologically advanced products. For instance, in 2018, Cerenovus, a division of the Johnson & Johnson Medical Devices Companies, launched the Galaxy G3 Mini embolic coil which is designed to have an irregular shape to enable the device to fill open spaces in cerebral aneurysms.
IMARC Group's latest report provides a deep insight into the global neuroendovascular coil market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the neuroendovascular coil market in any manner.
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic, Stryker Corporation, DePuy Synthes, Penumbra, Johnson & Johnson Services Inc., Terumo Corporation, Cardinal Health, Boston Scientific Corporation, Cook Medical Incorporated, Balt Extrusion, EndoShape, etc.